A Chinese company engaged in semi-invasive brain-computer interface became the first firm globally to get regulatory approval for commercial use. Within 12 days, different arms of the Chinese government - both at the national and local level - worked together to assign the product a medical insurance code, add it to the government’s consumables catalogue, and list it for hospital procurement. In contrast, it may be 2029 when Elon Musk's Neuralink gets its regulatory clearance.
Shobhankita Reddy sits down with Shambhavi Naik to discuss what all this means and its potential impact for China and the rest of the world.
Read Shobhankita's op-ed here - https://www.moneycontrol.com/news/opinion/china-s-laissez-faire-approach-to-cutting-edge-medical-technology-has-set-the-cat-among-the-pigeons-14021687.html
All Things Policy is a daily podcast on public policy brought to you by the Takshashila Institution, Bengaluru. Find out more on our research and other work here: https://takshashila.org.in/research-areas
Check out our public policy courses here: https://school.takshashila.org.in
